Sophiris Bio, which is developing a biologic to treat enlarged prostates, raised $65 million by offering 13.0 million shares at $5. The company had previously filed to offer 5.0 million shares at $13. Sophiris Bio plans to list on the NASDAQ under the symbol SPHS. Sophiris Bio initially filed confidentially on 12/7/2012. Citi and Leerink Swann acted as lead managers on the deal.
